CAR-T Development In Autoimmune Should Continue, FDA’s Marks Says; Malignancy Reports Not ‘Overly Concerning’

 
• By Sue Sutter
Bright horizon
The horizon remains bright for CAR-T products despite malignancy reports. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies